Breathing some half-life into Cialis

A recent hiccup at the FDA took Cialis from Lilly Icos LLC out of a dead heat with Bayer AG's vardenafil to become the second phosphodiesterase-5 inhibitor to reach the U.S. market for erectile dysfunction. But data presented at the American Urological Association (AUA) meeting in Orlando may give Lilly Icos the marketing hook it needs to grab market share once it gets final approval.

Both Cialis tadalafil and vardenafil are oral selective PDE-5 inhibitors, like Viagra sildenafil from Pfizer Inc. (PFE, New York, N.Y.). According to

Read the full 875 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE